GLP-1R agonists may also be beneficial for combating glaucoma among diabetic patients
GLP-1R agonists, a type of drug intervention used for the treatment of diabetes, may also be beneficial for combating glaucoma among patients, new research in the British Journal of Ophthalmology finds.
For the study, the data of nearly 2,000 patients with diabetes was looked at, all of which had just been administered GLP-1R agonists for the first time. Those participants were matched with nearly 4,350 unexposed control subjects.
“Glucagon-like peptide-1 receptor (GLP-1R) agonists regulate blood glucose and are commonly used to treat type 2 diabetes mellitus,” according to researchers.
“In this study, we used an insurance claims database (Clinformatics Data Mart) to examine whether GLP-1R agonist exposure impacts glaucoma risk.”
Based on the findings, the use of GLP-1R agonists was associated with a significantly lower risk of a diagnosis of glaucoma.
In spite of the findings, however, further research is warranted in using GLP-1R agonists to prevent glaucoma.